Earnings Call Excerpt
February 21, 2006
Executives:
William R. Ringo, Chief Executive Officer, President and Director
H. Ward Wolff, Chief Financial Officer, Senior Vice-President, Finance
Gisela Schwab, M.D., Chief Medical Officer
Greg Mann, Director of Corporate Communications and Investor Relations
Analysts:
Morgan Allen, Vegas Club, Inc
Manish Jain, CWP
Elise Wang, Citigroup
Brian Rye, Janney Montgomery
Presentation
Operator
Good day ladies and gentleman and welcome to the Abgenix 2005 Fourth Quarter and Year End Conference Call. At this time, I would like to inform you that all participants are in a listen-only mode. At the request of the company, we will open the conference up for questions and answers after the presentation. I would now like to introduce Greg Mann, Director of Corporate Communications and Investor Relations at Abgenix. Mr. Mann you may begin.
Greg Mann, Director of Corporate Communications and Investor Relations
Thank you Tab. Good afternoon and welcome to our 4th Quarter and Full Year 2005 Conference Call. Our call today will proceed as follows: Bill Ringo, President and CEO at Abgenix, will read out his highlights from the Quarter. Ward Wolff, our Chief Financial Officer, will then review our 4th Quarter and full year financial results. Dr. Gisela Schwab, our Chief Medical Officer, is also on the line today and will be available during the question and answer section of our call.
Before beginning we wish to remind listeners that during the course of this teleconference the company may make projections or other forward-looking statements regarding future events or financial performance. Abgenix cautions you that such statements reflect only the company’s current expectations and that actual events or results may differ materially from those discussed in the forward-looking statements.
For additional information regarding factors that could cause events or results to differ materially, please refer to the risk factors and cautionary language contained in the document that the company files from time to time with the Securities and Exchange Commission including its report on Form 10-K for the year ended December 31, 2004. The company undertakes no obligation to update any projections or forward-looking statements in the future.
I’ll now turn the call over to Bill Ringo.
William R. Ringo, Chief Executive Officer, President and Director
Thanks Greg, good afternoon to everyone and welcome to today’s call. The 4th Quarter of 2005 was clearly a very eventful period for our company, and I’d like to review the major highlights.
Working with our co-development partner, Amgen, we made excellent progress in the clinical development of panitumumab. As we announced in November last year, our pivotal study, Study 408, met its primary endpoint making our fully human monoclonal antibody the first EGFR inhibitor to show an improvement in progression-free survival as a single agent for metastatic colorectal cancer patients who have failed standard chemotherapy, including irinotecan and/or oxaliplatin. The observed improvement is significant and the study data supports the flexible dosing and excellent safety profile of panitumumab.
Thank you. Ladies and gentleman if you’d like to ask a question, please press ?*1
- To read the full transcript on Seeking Alpha, click here »
